Baird reiterated an Outperform rating and $202.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) following a quarterly update. Exondys51 sales ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Sarepta Therapeutics (SRPT) Gains 8.5% Off the OpenAugust 9, 2018 9:40 AM Sarepta Therapeutics (SRPT) PT Lowered to $187 at RBC CapitalAugust 9, 2018 8:48 AM After-Hours Stock Movers 08/08: (YELP) (SAIL) (ROKU) Higher; (ACAD) (AMPE) (ELF) Lower (more...)August 8, 2018 6:22 PM Sarepta Therapeutics (SRPT) Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics,August 8, 2018 4:22 PM Sarepta Therapeutics (SRPT) Posts Smaller Q2 Loss on Higher RevenuesAugust 8, 2018 4:21 PM Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate DevelopmentsAugust 8, 2018 4:02 PM Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene TAugust 8, 2018 4:01 PM Sarepta Therapeutics (SRPT) calls active into EPSAugust 7, 2018 5:07 AM